Kyntra Bio, Inc. (KYNB)
4.85
-0.51
(-9.51%)
USD |
NASDAQ |
Oct 16, 16:00
5.10
+0.25
(+5.15%)
After-Hours: 20:00
Kyntra Bio Research and Development Expense (Annual) : 23.52M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 23.52M |
| December 31, 2024 | 95.69M |
| December 31, 2023 | 263.16M |
| December 31, 2022 | 296.79M |
| December 31, 2021 | 387.04M |
| December 31, 2020 | 252.92M |
| December 31, 2019 | 209.26M |
| Date | Value |
|---|---|
| December 31, 2018 | 235.84M |
| December 31, 2017 | 196.52M |
| December 31, 2016 | 187.21M |
| December 31, 2015 | 214.09M |
| December 31, 2014 | 150.79M |
| December 31, 2013 | 85.71M |
| December 31, 2012 | 74.22M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Vericel Corp. | 27.56M |
| Nektar Therapeutics | 117.07M |
| Capricor Therapeutics, Inc. | 83.50M |
| ARS Pharmaceuticals, Inc. | 13.18M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |